Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) announced a share reduction plan by its controlling shareholder and actual controller, Tu Shanzeng, who intends to reduce his holdings in the company within a specified timeframe [1] Group 1: Share Reduction Plan - Tu Shanzeng holds 10,479,056 shares, representing 3.01% of the total share capital, and plans to reduce his holdings by up to 3,479,771 shares (1.00%) through centralized bidding and up to 6,959,543 shares (2.00%) via block trading within three months starting from July 18, 2025 [1] Group 2: Fundraising and Financials - Tianyu Co., Ltd. raised a total of 899,999,995.30 RMB by issuing 11,117,974 shares at 80.95 RMB per share, with a net amount of 894,058,095.09 RMB after deducting related expenses [2] - The company distributed cash dividends of 5 RMB per 10 shares, totaling 96,660,322.00 RMB, and also increased its capital stock by 8 shares for every 10 shares held [3] Group 3: Convertible Bonds - The company planned to issue convertible bonds with a total amount not exceeding 140 million RMB, intended for a project to produce 6 billion solid dosage forms and to supplement working capital [4] - The proposal for issuing convertible bonds automatically expired as of July 3, 2024, after the necessary approvals were obtained [4]

证券代码：300702 证券简称：天宇股份 公告编号：2025-040 浙江天宇药业股份有限公司 关于控股股东、实际控制人之一致行动人减持股份 的预披露公告 信息披露义务人控股股东、实际控制人之一致行动人屠善增保证信息披露 的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 浙江天宇药业股份有限公司（以下简称"公司"）于近日收到控股股东、实 际控制人之一致行动人屠善增先生的《关于公司股份减持计划的告知函》，屠善 增先生持有公司股份 10,479,056 股（占公司总股本的比例为 3.01%），计划在自 本公告披露之日起十五个交易日后的三个月内（即 2025 年 7 月 18 日至 2025 年 10 月 15 日），以集中竞价方式减持公司股份不超过 3,479,771 股（占本公司总 股本比例 1.00%），以大宗交易方式减持公司股份不超过 6,959,543 股（占本公司 总股本比例 2.00%）。现将有关情况公告如下： 二、本次减持计划的主要内容 （一）本次减持计划的具体安排 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 ...

Summary of Key Points from Conference Call Records Industry Overview - The orthopedic consumables industry is experiencing significant changes, with a notable increase in domestic production rates due to centralized procurement policies. The orthopedic market is segmented into joint replacement, spine surgery, trauma, and sports medicine, with joint replacement accounting for a substantial market share of over 30% [24][25]. Core Insights and Arguments - The pharmaceutical sector has shown a 4.56% increase year-to-date, ranking sixth among 31 primary industries, despite a recent decline of 4.35% [2]. The innovation drug sector remains promising, with expectations for a rebound in the second half of 2025, particularly in non-oncology areas [1][5]. - The high-value consumables sector is highlighted, with recommendations for companies like Huatai and Microelectrophysiology in the electrophysiology space, and Spring Medical as a leading player in orthopedics with over 40% of revenue from overseas markets [2][9]. - The Chinese government is actively supporting high-end medical device innovation, focusing on areas such as medical robots, high-end imaging equipment, and AI medical devices, with companies like Mindray, United Imaging, and Aohua Medical being key players [6][8]. - The traditional Chinese medicine sector is expected to improve in the latter half of 2025, driven by decreasing procurement costs and clearer planning frameworks under the 14th Five-Year Plan [11]. Additional Important Content - The orthopedic consumables market is projected to maintain a stable growth rate of nearly 10% annually, with companies like Spring Medical leading the charge in international markets [27]. - The domestic orthopedic consumables market has seen a significant increase in localization rates, with joint replacement at 79% and spine products at 80% [25]. - The innovation drug sector is undergoing a necessary adjustment after a period of rapid growth, with expectations for valuations to stabilize in the coming weeks [4][5]. - The raw materials sector is also viewed positively, with companies focusing on high-end businesses and new product launches as patent expirations approach [17][18]. This summary encapsulates the key points from the conference call records, providing insights into the current state and future prospects of the pharmaceutical and orthopedic consumables industries.

一、药品基本情况 药品名称：厄贝沙坦（工艺 II） 药品生产商/持有人：浙江天宇药业股份有限公司 生产地址：浙江省台州市 证书编号：CEP 2025-025 - Rev 00 发证机构：欧洲药品质量管理局 有效期：自 2025 年 5 月 15 日起五年内 二、药品的其他相关情况 厄贝沙坦属于降血压药物，治疗原发性高血压，合并高血压的 2 型糖尿病肾 病的治疗。 证券代码：300702 证券简称：天宇股份 公告编号：2025-040 浙江天宇药业股份有限公司 关于公司原料药获得 CEP 证书的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下简称"公司"）收到欧洲药品质量管理局 （以下简称"EDQM"）签发的关于厄贝沙坦（工艺 II）原料药的欧洲药典适用 性认证证书（以下简称"CEP 证书"），现将相关情况公告如下： 公司于 2024 年 12 月向 EDQM 递交了厄贝沙坦（工艺 II）原料药的药品注 册申请并获得 CEP 证书。 三、对公司的影响及风险提示 截至目前，公司厄贝沙坦原料药共 ...

浙江天宇药业股份有限公司 关于全资子公司药品获得批准的公告 证券代码：300702 证券简称：天宇股份 公告编号：2025-039 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下简称"公司"）全资子公司浙江诺得药业 有限公司（以下简称"诺得药业"）于近日收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的关于孟鲁司特钠片的《药品注册证书》。现将相关 情况公告如下： 一、药品情况 1、药品基本情况 | 药品名称 | 孟鲁司特钠片 | | | | --- | --- | --- | --- | | 英文名 | Montelukast Sodium Tablets | | | | 剂型 | 片剂 | | | | 规格 | 10mg（按 C35H36ClNO3S | | 计） | | 是否处方药 | 是 | | | | 申请事项 | 药品注册（境内生产） | | | | 注册分类 | 化学药品 类 4 | | | | 药品批准文号 | 国药准字 H20254487 | | | | 药品批准文号 ...

Core Viewpoint - Tianyu Co., Ltd. has received the European Pharmacopoeia Certificate of Suitability (CEP) for its raw material drug Eprosartan, which is used for treating primary hypertension and diabetic nephropathy associated with hypertension [1] Group 1 - The company submitted its drug registration application in December 2024 and obtained the CEP certificate, numbered CEP2025-025-Rev00, which is valid for five years starting from May 15, 2025 [1] - Eprosartan is classified as an antihypertensive medication, indicating its significance in the treatment of high blood pressure [1] - The company now holds two CEP certificates for Eprosartan raw materials, which is expected to positively impact its efforts to expand into international markets [1]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [3] Core Insights - The report emphasizes the arrival of a new era for innovative drugs, highlighting the strong performance of the sector in May 2025, with a 6.4% increase in the pharmaceutical and biotechnology sector, outperforming the CSI 300 index by 4.6% [10][22] - It suggests a focus on companies transitioning from biotech to biopharma and those in traditional pharma that are innovating [9] - The report identifies significant investment opportunities in AI-driven healthcare and medical services, indicating that the industry is just beginning to harness the potential of artificial intelligence [9] - The report anticipates a recovery in performance and valuation for CRO&CDMO, upstream research, and specialty raw materials, with Q2 performance expected to improve [9][11] Summary by Sections June Industry Investment Outlook - The report encourages embracing the innovative drug era and actively positioning for Q2 performance [9] - It highlights key recommended stocks for June, including WuXi AppTec, Sangamo Therapeutics, Changchun High-tech, Betta Pharmaceuticals, Nanwei Medical, Kunming Pharmaceutical, Nuotai Biological, Dian Diagnostics, Tianyu Co., and Boan Biotechnology [12] Market Dynamics - In May 2025, the pharmaceutical sector saw all sub-sectors increase, with chemical pharmaceuticals rising by 9.77%, biological products by 7.29%, and medical services by 6.00% [10][22] - The report notes that the pharmaceutical sector's valuation is currently at 23.4 times PE, with a premium of 29.3% over the broader A-share market [27] Key Company Performances - The report highlights the record-breaking BD transaction of 1.25 billion USD by Sangamo Therapeutics, which has catalyzed investment enthusiasm in innovative drugs [10] - It mentions that 71 original research results from Chinese pharmaceutical companies were presented at ASCO, showcasing their growing international competitiveness [10] Investment Recommendations - The report recommends focusing on companies with strong growth potential, such as WuXi AppTec, Sangamo Therapeutics, and Changchun High-tech, among others [12][14] - It also suggests monitoring companies in the AI healthcare sector and those poised for recovery in the traditional pharmaceutical space [9][11]

Group 1 - The A-share chemical pharmaceutical sector experienced a significant rise at the beginning of trading, with Hainan Haiyao and Huahai Pharmaceutical both hitting the daily limit up [1] - Tianyu Co., Ltd. saw an increase of over 10%, indicating strong market interest [1] - Other companies such as Jincheng Pharmaceutical, Saito Biological, Microchip Biotech, Lukang Pharmaceutical, and Nawei Technology also experienced gains, reflecting a broader positive trend in the sector [1]

1、经公司 2024 年度股东大会审议通过的利润分配预案为：公司本次的利润 分配以实施权益分派股权登记日登记的享有利润分配权的股本为基数，向全体股 东每 10 股派发现金股利 0.5 元（含税）,其余未分配利润结转下年。本次利润分 配不送红股、不进行资本公积金转增股本。自本公告披露至利润分配方案实施前， 若公司前述总股数由于股份回购等情形而发生变化,公司将按照"分配比例不变" 的原则,相应调整分配总额。截至本公告日，公司总股本为 347,977,159 股，合 计派发现金红利总金额为 17,398,857.95 元（含税）。 2、自权益分派方案披露至实施期间公司股本总额未发生变化。 3、本次实施的权益分派方案与股东大会审议通过的权益分派方案一致。 4、本次实施权益分派方案距离股东大会审议通过的时间未超过两个月。 证券代码：300702 证券简称：天宇股份 公告编号：2025-038 浙江天宇药业股份有限公司 关于 2024 年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下 ...

证券代码：300702 证券简称：天宇股份 公告编号：2025-037 浙江天宇药业股份有限公司 关于 2024 年员工持股计划第一个锁定期届满的提示性公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下简称公司）《2024 年员工持股计划》（以 下简称"本次员工持股计划"或"本计划"）第一个锁定期将于 2025 年 5 月 28 日届满。根据《关于上市公司实施员工持股计划试点的指导意见》《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关规定及 本次员工持股计划的相关内容，现将本次员工持股计划第一个锁定期届满及解锁 情况公告如下： 一、本次员工持股计划的基本情况 （一）本次员工持股计划的基本情况 公司于 2024 年 2 月 21 日召开第五届董事会第六次会议和第五届监事会第 六次会议，审议通过《关于<浙江天宇药业股份有限公司 2024 年员工持股计划 （草案）>及其摘要的议案》《关于<浙江天宇药业股份有限公司 2024 年员工持 股计划管理办法>的议案》等相关 ...